Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7 years following immunization with either Cervarix® or Gardasil® vaccine

Kavita Panwar; Anna Godi; Clementina E. Cocuzza; Nick Andrews; Jo Southern; Paul Turner; Elizabeth Miller; Simon Beddows

doi:10.1016/j.vaccine.2022.01.041

Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7 years following immunization with either Cervarix® or Gardasil® vaccine

Kavita Panwar
, Anna Godi
, Clementina E. Cocuzza
, Nick Andrews
, Jo Southern
, Paul Turner
, Elizabeth Miller
, Simon Beddows^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Abstract

Human Papillomavirus (HPV) bivalent (Cervarix®) and quadrivalent (Gardasil®) vaccines demonstrate robust efficacy against vaccine types and cross-protection against related non-vaccine types. Here we evaluate the breadth, magnitude and durability of the vaccine-induced antibody response against vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) type antigens up to 7 years following vaccination of 12-15 year old girls in a three dose schedule and contrast these data with the levels of antibody typically seen in natural infection. Vaccine-type antibody levels waned over the 7-year follow up period but remained at least an order of magnitude above the typical antibody levels elicited by natural infection. Seropositivity to non-vaccine types remained high 7 years after initial vaccination, but antibody levels approached those typically generated following natural infection. Empirical data on the breadth, magnitude, specificity and durability of the immune response elicited by the HPV vaccines contribute to improving the evidence base supporting this important public health intervention.

Original language	English
Pages (from-to)	1198-1202
Number of pages	5
Journal	Vaccine
Volume	40
Issue number	9
Early online date	1 Feb 2022
DOIs	https://doi.org/10.1016/j.vaccine.2022.01.041
Publication status	Published - 23 Feb 2022

Bibliographical note

Funding Information: This work was supported by the UK Health Security Agency. This publication is independent research part funded by the National Institute for Health Research Policy Research Programme (“Vaccine Evaluation Consortium Phase II”, 039/0031). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care.

Open Access: No Open Access licence.

Publisher Copyright: Crown Copyright © 2022. Published by Elsevier Ltd. All rights reserved.

Citation: Panwar, Kavita, et al. "Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7 years following immunization with either Cervarix® or Gardasil® vaccine." Vaccine (2022).

DOI: https://doi.org/10.1016/j.vaccine.2022.01.041

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Antibody
Durability
Human papillomavirus
Vaccine

Access to Document

10.1016/j.vaccine.2022.01.041

Cite this

@article{49cfd99adbe6411ab34faf22b6a1669d,

title = "Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7 years following immunization with either Cervarix{\textregistered} or Gardasil{\textregistered} vaccine",

abstract = "Human Papillomavirus (HPV) bivalent (Cervarix{\textregistered}) and quadrivalent (Gardasil{\textregistered}) vaccines demonstrate robust efficacy against vaccine types and cross-protection against related non-vaccine types. Here we evaluate the breadth, magnitude and durability of the vaccine-induced antibody response against vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) type antigens up to 7 years following vaccination of 12-15 year old girls in a three dose schedule and contrast these data with the levels of antibody typically seen in natural infection. Vaccine-type antibody levels waned over the 7-year follow up period but remained at least an order of magnitude above the typical antibody levels elicited by natural infection. Seropositivity to non-vaccine types remained high 7 years after initial vaccination, but antibody levels approached those typically generated following natural infection. Empirical data on the breadth, magnitude, specificity and durability of the immune response elicited by the HPV vaccines contribute to improving the evidence base supporting this important public health intervention.",

keywords = "Antibody, Durability, Human papillomavirus, Vaccine",

author = "Kavita Panwar and Anna Godi and Cocuzza, \{Clementina E.\} and Nick Andrews and Jo Southern and Paul Turner and Elizabeth Miller and Simon Beddows",

note = "Funding Information: This work was supported by the UK Health Security Agency. This publication is independent research part funded by the National Institute for Health Research Policy Research Programme (“Vaccine Evaluation Consortium Phase II”, 039/0031). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care. Open Access: No Open Access licence. Publisher Copyright: Crown Copyright {\textcopyright} 2022. Published by Elsevier Ltd. All rights reserved. Citation: Panwar, Kavita, et al. {"}Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7 years following immunization with either Cervarix{\textregistered} or Gardasil{\textregistered} vaccine.{"} Vaccine (2022). DOI: https://doi.org/10.1016/j.vaccine.2022.01.041",

year = "2022",

month = feb,

day = "23",

doi = "10.1016/j.vaccine.2022.01.041",

language = "English",

volume = "40",

pages = "1198--1202",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "9",

}

TY - JOUR

T1 - Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7 years following immunization with either Cervarix® or Gardasil® vaccine

AU - Panwar, Kavita

AU - Godi, Anna

AU - Cocuzza, Clementina E.

AU - Andrews, Nick

AU - Southern, Jo

AU - Turner, Paul

AU - Miller, Elizabeth

AU - Beddows, Simon

N1 - Funding Information: This work was supported by the UK Health Security Agency. This publication is independent research part funded by the National Institute for Health Research Policy Research Programme (“Vaccine Evaluation Consortium Phase II”, 039/0031). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care. Open Access: No Open Access licence. Publisher Copyright: Crown Copyright © 2022. Published by Elsevier Ltd. All rights reserved. Citation: Panwar, Kavita, et al. "Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7 years following immunization with either Cervarix® or Gardasil® vaccine." Vaccine (2022). DOI: https://doi.org/10.1016/j.vaccine.2022.01.041

PY - 2022/2/23

Y1 - 2022/2/23

N2 - Human Papillomavirus (HPV) bivalent (Cervarix®) and quadrivalent (Gardasil®) vaccines demonstrate robust efficacy against vaccine types and cross-protection against related non-vaccine types. Here we evaluate the breadth, magnitude and durability of the vaccine-induced antibody response against vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) type antigens up to 7 years following vaccination of 12-15 year old girls in a three dose schedule and contrast these data with the levels of antibody typically seen in natural infection. Vaccine-type antibody levels waned over the 7-year follow up period but remained at least an order of magnitude above the typical antibody levels elicited by natural infection. Seropositivity to non-vaccine types remained high 7 years after initial vaccination, but antibody levels approached those typically generated following natural infection. Empirical data on the breadth, magnitude, specificity and durability of the immune response elicited by the HPV vaccines contribute to improving the evidence base supporting this important public health intervention.

AB - Human Papillomavirus (HPV) bivalent (Cervarix®) and quadrivalent (Gardasil®) vaccines demonstrate robust efficacy against vaccine types and cross-protection against related non-vaccine types. Here we evaluate the breadth, magnitude and durability of the vaccine-induced antibody response against vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) type antigens up to 7 years following vaccination of 12-15 year old girls in a three dose schedule and contrast these data with the levels of antibody typically seen in natural infection. Vaccine-type antibody levels waned over the 7-year follow up period but remained at least an order of magnitude above the typical antibody levels elicited by natural infection. Seropositivity to non-vaccine types remained high 7 years after initial vaccination, but antibody levels approached those typically generated following natural infection. Empirical data on the breadth, magnitude, specificity and durability of the immune response elicited by the HPV vaccines contribute to improving the evidence base supporting this important public health intervention.

KW - Antibody

KW - Durability

KW - Human papillomavirus

KW - Vaccine

UR - https://www.scopus.com/pages/publications/85123857656

U2 - 10.1016/j.vaccine.2022.01.041

DO - 10.1016/j.vaccine.2022.01.041

M3 - Article

AN - SCOPUS:85123857656

SN - 0264-410X

VL - 40

SP - 1198

EP - 1202

JO - Vaccine

JF - Vaccine

IS - 9

ER -

Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7 years following immunization with either Cervarix® or Gardasil® vaccine

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this